Our Shielded-Cell and Immunotherapy Pairs represent a fundamentally new approach to cellular therapy. We believe our technology platform has the potential to significantly improve HSC transplant, and will one day allow it to be given as an outpatient procedure in some circumstances.
Tom Home Page
